Long-term follow-up from the SOFT study shows adding ovarian function suppression (OFS) for premenopausal women under 35 with HR-positive breast cancer yields an 18% absolute improvement in breast cancer-free interval. The speaker notes these gains are unprecedented since the introduction of trastuzumab, highlighting OFS as a critical, high-impact intervention for this specific patient group.
While the SOFT trial established a five-year standard for ovarian function suppression (OFS), new registry data indicates that continuing OFS beyond five years, often towards 10 years or natural menopause, further reduces recurrence risk. This evidence supports considering a longer duration of OFS for many premenopausal women to maximize long-term, robust benefits.
Despite proven benefits, side effects from adjuvant CDK4/6 inhibitors like abemaciclib create significant adherence challenges. The speaker notes that in practice, almost no patient completes the full multi-year course at the starting dose. Even in a supportive study, 20% of patients discontinued therapy within six months, highlighting a critical gap between trial efficacy and real-world tolerability.
Current data does not support replacing chemotherapy with CDK4/6 inhibitors in the neoadjuvant setting for high-risk, ER-positive breast cancer. The Carabella study showed chemotherapy achieved better pathological responses than letrozole plus abemaciclib, particularly in premenopausal women. This indicates these targeted agents are additive to, not a replacement for, standard chemotherapy.
The LIDERA trial's early, robust success with the oral SERD giredestrant in adjuvant therapy is surprising. In the metastatic setting, these drugs primarily benefit tumors with ESR1 mutations, which are acquired after therapy and rare at diagnosis. This paradoxical result suggests a different mechanism of action in early-stage disease and necessitates longer follow-up to confirm the finding.
Patients in recent international adjuvant trials like MONARCH-E, NATALI, and LADERA have a significantly higher baseline risk of recurrence compared to those in US-centric studies like TaylorX. Three-year event rates are two to four times higher, which is critical context for applying these findings and assessing the cost-benefit of new, toxic therapies for average-risk patients.